Hans Einar Krokan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Einar Krokan has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Geir Slupphaug
Department of Clinical and Molecular Medicine, NTNU, Norway
10 shared publications Per Arne Aas
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway
6 shared publicationsBodil Kavli
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NO-7489 Trondheim, Norway
5 shared publicationsHenrik Sahlin Pettersen
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway; Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olav's Hospital, Trondheim University Hospital, NO-7006 Trondheim, Norway
4 shared publications- Marit Otterlei
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU)
4 shared publications - Pål Sætrom
Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway; Department of Computer Science, NTNU, Trondheim, Norway
4 shared publications
Latest Publications
- Open Access
- 19 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (8) , 4212
Genomic Uracil and Aberrant Profile of Demethylation Intermediates in Epigenetics and Hematologic Malignancies
DNA of all living cells undergoes continuous structural and chemical alterations resulting from fundamental cellular metabolic processes and reactivity of normal cellular metabolites and constituents. Examples include enzymatically oxidized bases, aberrantly methylated bases, and deaminated bases, the latter largely uracil from deaminated cytosine. In addition, the non-canonical DNA base uracil may result from misincorporated dUMP. Furthermore, uracil generated by deamination of cytosine in DNA is not always damage as it is also an intermediate in normal somatic hypermutation (SHM) and class shift recombination (CSR) at the Ig locus of B-cells in adaptive immunity. Many of the modifications alter base-pairing properties and may thus cause replicative and transcriptional mutagenesis. The best known and most studied epigenetic mark in DNA is 5-methylcytosine (5mC), generated by a methyltransferase that uses SAM as methyl donor, usually in CpG contexts. Oxidation products of 5mC are now thought to be intermediates in active demethylation as well as epigenetic marks in their own rights. The aim of this review is to describe the endogenous processes that surround the generation and removal of the most common types of DNA nucleobase modifications, namely, uracil and certain epigenetic modifications, together with their role in the development of hematological malignances. We also discuss what dictates whether the presence of an altered nucleobase is defined as damage or a natural modification.
- 19 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (8) , 4212
Open AccessGenomic Uracil and Aberrant Profile of Demethylation Intermediates in Epigenetics and Hematologic Malignancies
DNA of all living cells undergoes continuous structural and chemical alterations resulting from fundamental cellular metabolic processes and reactivity of normal cellular metabolites and constituents. Examples include enzymatically oxidized bases, aberrantly methylated bases, and deaminated bases, the latter largely uracil from deaminated cytosine. In addition, the non-canonical DNA base uracil may result from misincorporated dUMP. Furthermore, uracil generated by deamination of cytosine in DNA is not always damage as it is also an intermediate in normal somatic hypermutation (SHM) and class shift recombination (CSR) at the Ig locus of B-cells in adaptive immunity. Many of the modifications alter base-pairing properties and may thus cause replicative and transcriptional mutagenesis. The best known and most studied epigenetic mark in DNA is 5-methylcytosine (5mC), generated by a methyltransferase that uses SAM as methyl donor, usually in CpG contexts. Oxidation products of 5mC are now thought to be intermediates in active demethylation as well as epigenetic marks in their own rights. The aim of this review is to describe the endogenous processes that surround the generation and removal of the most common types of DNA nucleobase modifications, namely, uracil and certain epigenetic modifications, together with their role in the development of hematological malignances. We also discuss what dictates whether the presence of an altered nucleobase is defined as damage or a natural modification.
- Open Access
- 19 October 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 295
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disappointingly few molecules or techniques that are in use today. The “1st International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation”, was held June 16th and 17th 2016, at the Knowledge Center of the St. Olavs Hospital in Trondheim, Norway, under the auspices of the Norwegian University of Science and Technology (NTNU) and the HUNT biobank and research center. The Symposium attracted approximately 100 attendees and invited speakers from 12 countries and 4 continents. In this Symposium original research and overviews on diagnostic, predictive and prognostic cancer biomarkers in serum, plasma, urine, pleural fluid and tumor, circulating tumor cells and bioinformatics as well as how to implement biomarkers in clinical trials were presented. Senior researchers and young investigators presented, reviewed and vividly discussed important new developments in the field of clinical biomarkers of cancer, with the goal of accelerating biomarker research and implementation. The excerpts of this symposium aim to give a cutting-edge overview and insight on some highly important aspects of clinical cancer biomarkers to-date to connect molecular innovation with clinical implementation to eventually improve patient care.
- 19 October 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 295
Open AccessExcerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disappointingly few molecules or techniques that are in use today. The “1st International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation”, was held June 16th and 17th 2016, at the Knowledge Center of the St. Olavs Hospital in Trondheim, Norway, under the auspices of the Norwegian University of Science and Technology (NTNU) and the HUNT biobank and research center. The Symposium attracted approximately 100 attendees and invited speakers from 12 countries and 4 continents. In this Symposium original research and overviews on diagnostic, predictive and prognostic cancer biomarkers in serum, plasma, urine, pleural fluid and tumor, circulating tumor cells and bioinformatics as well as how to implement biomarkers in clinical trials were presented. Senior researchers and young investigators presented, reviewed and vividly discussed important new developments in the field of clinical biomarkers of cancer, with the goal of accelerating biomarker research and implementation. The excerpts of this symposium aim to give a cutting-edge overview and insight on some highly important aspects of clinical cancer biomarkers to-date to connect molecular innovation with clinical implementation to eventually improve patient care.
- Open Access
- 1 June 2015
- Published by Elsevier in DNA Repair
- Vol. 30, 53-67
Cell cycle regulation of human DNA repair and chromatin remodeling genes
- 1 June 2015
- Published by Elsevier in DNA Repair
- Vol. 30, 53-67
Open AccessCell cycle regulation of human DNA repair and chromatin remodeling genes
- Open Access
- 1 January 2015
- Published by Elsevier in DNA Repair
- Vol. 25, 60-71
AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature
- 1 January 2015
- Published by Elsevier in DNA Repair
- Vol. 25, 60-71
Open AccessAID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature
- 1 July 2014
- Published by Elsevier in Molecular Immunology
- Vol. 60 (1) , 23-31
Expression and recruitment of uracil-DNA glycosylase are regulated by E2A during antibody diversification
- 1 July 2014
- Published by Elsevier in Molecular Immunology
- Vol. 60 (1) , 23-31
Expression and recruitment of uracil-DNA glycosylase are regulated by E2A during antibody diversification
- Open Access
- 1 July 2014
- Published by Elsevier in DNA Repair
- Vol. 19, 38-47
Error-free versus mutagenic processing of genomic uracil—Relevance to cancer
- 1 July 2014
- Published by Elsevier in DNA Repair
- Vol. 19, 38-47
Open AccessError-free versus mutagenic processing of genomic uracil—Relevance to cancer
- Open Access
- 1 March 2014
- Published by Elsevier in Experimental Cell Research
- Vol. 322 (1) , 178-192
Activation-induced cytidine deaminase (AID) is localized to subnuclear domains enriched in splicing factors
- 1 March 2014
- Published by Elsevier in Experimental Cell Research
- Vol. 322 (1) , 178-192
Open AccessActivation-induced cytidine deaminase (AID) is localized to subnuclear domains enriched in splicing factors
- Top Cited Papers
- 1 April 2013
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 5 (4) , a012583
Base Excision Repair
Base excision repair (BER) corrects DNA damage from oxidation, deamination and alkylation. Such base lesions cause little distortion to the DNA helix structure. BER is initiated by a DNA glycosylase that recognizes and removes the damaged base, leaving an abasic site that is further processed by short-patch repair or long-patch repair that largely uses different proteins to complete BER. At least 11 distinct mammalian DNA glycosylases are known, each recognizing a few related lesions, frequently with some overlap in specificities. Impressively, the damaged bases are rapidly identified in a vast excess of normal bases, without a supply of energy. BER protects against cancer, aging, and neurodegeneration and takes place both in nuclei and mitochondria. More recently, an important role of uracil-DNA glycosylase UNG2 in adaptive immunity was revealed. Furthermore, other DNA glycosylases may have important roles in epigenetics, thus expanding the repertoire of BER proteins.
- 1 April 2013
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 5 (4) , a012583
Top Cited PapersBase Excision Repair
Base excision repair (BER) corrects DNA damage from oxidation, deamination and alkylation. Such base lesions cause little distortion to the DNA helix structure. BER is initiated by a DNA glycosylase that recognizes and removes the damaged base, leaving an abasic site that is further processed by short-patch repair or long-patch repair that largely uses different proteins to complete BER. At least 11 distinct mammalian DNA glycosylases are known, each recognizing a few related lesions, frequently with some overlap in specificities. Impressively, the damaged bases are rapidly identified in a vast excess of normal bases, without a supply of energy. BER protects against cancer, aging, and neurodegeneration and takes place both in nuclei and mitochondria. More recently, an important role of uracil-DNA glycosylase UNG2 in adaptive immunity was revealed. Furthermore, other DNA glycosylases may have important roles in epigenetics, thus expanding the repertoire of BER proteins.
- 1 March 2012
- Published by Elsevier in DNA Repair
- Vol. 11 (3) , 224-235
A life in DNA repair—And beyond
- 1 March 2012
- Published by Elsevier in DNA Repair
- Vol. 11 (3) , 224-235
A life in DNA repair—And beyond
- 1 December 2011
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 87 (3) , 363-367
A new high resolution screening method for study of phenotype stress responses of Saccharomyces cerevisae mutants
- 1 December 2011
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 87 (3) , 363-367
A new high resolution screening method for study of phenotype stress responses of Saccharomyces cerevisae mutants